Journal
BIOTECHNOLOGY JOURNAL
Volume 15, Issue 2, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/biot.201900191
Keywords
cascade enzymes; cofactor-free; Myo-inositol; Scyllo-inositol; whole-cell biotransformation
Funding
- Key Research Program of the Chinese Academy of Sciences [ZDRW-ZS-2016-3]
- National Natural Science Foundation of China [21778073]
- Key Projects in the Tianjin Science & Technology Pillar Program [15PTCYSY00020]
- 1000-Youth Talent Program of China
- Sichuan Science and Technology Project [2016JZ0023]
Ask authors/readers for more resources
Scyllo-inositol (SI), a stereoisomer of inositol, is regarded as a promising therapeutic agent for Alzheimer's disease. Here, an in vitro cofactor-balance biotransformation for the production of SI from myo-inositol (MI) by thermophilic myo-inositol 2-dehydrogenase (IDH) and scyllo-inositol 2-dehydrogenase (SIDH) is presented. These two enzymes (i.e., IDH and SIDH from Geobacillus kaustophilus) are co-expressed in Escherichia coli BL21(DE3), and E. coli cells containing the two enzymes are permeabilized by heat treatment as whole-cell catalysts to convert MI to SI. After condition optimizations about permeabilized temperature, reaction temperature, and initial MI concentration, about 82 g L-1 of SI is produced from 250 g L-1 of MI within 24 h without any cofactor supplementation. This final titer of SI produced is the highest to the authors' limited knowledge. This study provides a promising method for the large-scale industrial production of SI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available